Nelipepimut-S
DRACPC ID DRACPC0065
Active Ingredients Nelipepimut-S
Description A cancer vaccine comprised of a human leukocyte antigen (HLA) A2/A3 restricted HER2/neu (human epidermal growth factor receptor 2; ErbB2) nonapeptide derived from the extracellular domain of the HER2 protein, with potential immunomodulating and antineoplastic activities. Upon intradermal injection, nelipepimut-S may induce a specific cytotoxic T-lymphocyte (CTL) response against HER2/neu-expressing tumor cells. HER2/neu, a tumor-associated antigen and a member of the epidermal growth factor receptor family of tyrosine kinases, is overexpressed in various tumor cell types and plays a key role in tumorigenesis.
Synonyms E75 Peptide; NeuVax; Human Receptor Tyrosine-Protein Kinase erbB-2 (Proto-Oncogene Neu, Tyrosine Kinase- type Cell Surface Receptor HER2, CD340)-(347-355)-Peptide; L-Leucine, L-lysyl-L-isoleucyl-L-phenylalanylglycyl-L-seryl-L-leucyl-L-alanyl-L- phenylalanyl-; Nelipepimut S; Nelipepimut-S
Type Biotech
Disease Prostate cancer, Breast cancer
Classification
Peptide and derivative Vaccine
Structure Information
Molecular Formula C50H78N10O11
Molecular Weight 995.2
Active Sequence KIFGSLAFL
Sequence Length 9
Modification None
IUPAC Name (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
InChI InChI=1S/C50H78N10O11/c1-8-31(6)42(60-44(64)35(52)21-15-16-22-51)49(69)58-37(25-33-17-11-9-12-18-33)45(65)53-27-41(62)55-40(28-61)48(68)57-36(23-29(2)3)46(66)54-32(7)43(63)56-38(26-34-19-13-10-14-20-34)47(67)59-39(50(70)71)24-30(4)5/h9-14,17-20,29-32,35-40,42,61H,8,15-16,21-28,51-52H2,1-7H3,(H,53,65)(H,54,66)(H,55,62)(H,56,63)(H,57,68)(H,58,69)(H,59,67)(H,60,64)(H,70,71)/t31-,32-,35-,36-,37-,38-,39-,40-,42-/m0/s1
InChI_Key AHOKKYCUWBLDST-QYULHYBRSA-N
SMILES CC(C)C[C@@H](C(O)=O)NC([C@@H](NC([C@H](C)NC([C@H](CC(C)C)NC([C@H](CO)NC(CNC([C@@H](NC([C@@H](NC([C@@H](N)CCCCN)=O)[C@@H](C)CC)=O)CC1=CC=CC=C1)=O)=O)=O)=O)=O)CC2=CC=CC=C2)=O
External Codes
PubChem CID 9941306
DrugBank Accession Number DB06226
NCI Thesaurus Code C117985
UNII 7M0A29CD8B GSRS
CAS 160212-35-1
Drug approval
Drug indication
Investigated for use/treatment in prostate cancer and breast cancer.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT02636582 | VADIS Trial: Phase II Trial of Nelipeimut-S Peptide Vaccine in Women With DCIS of the Breast | Breast Ductal Carcinoma In Situ | Phase 2 | Prevention |
| NCT02297698 | Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax™) and Trastuzumab in High-risk HER2+ Breast Cancer Patients | Breast Cancer | Phase 2 | Prevention |
| NCT01479244 | PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment | Breast Cancer With Low to Intermediate HER2 Expression | Phase 3 | Prevention |
| NCT01570036 | Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence | Breast Cancer | Phase 2 | Prevention |
More clinical information is obtained from ClinicalTrials.gov.
